Tirzepatide's Market Volume Growth Rate
Tirzepatide (Mounjaro/Zepbound by Eli Lilly) launched in 2022 for diabetes and 2023 for obesity, achieving explosive U.S. sales growth. Global sales hit $5.3 billion in 2023 (first full year), surging to $19.2 billion in 2024—a 262% year-over-year increase. Quarterly U.S. prescriptions rose from 100,000 in Q4 2022 to over 2.3 million by Q4 2024, capturing 35% of the GLP-1 market share by volume in obesity treatments.[1][2]
Liraglutide's Historical Trajectory
Liraglutide (Victoza/Saxenda by Novo Nordisk) launched in 2010 for diabetes and 2015 for obesity. Peak annual sales reached $3.5 billion in 2019 after nearly a decade on market. U.S. prescriptions grew steadily but plateaued: from ~500,000 quarterly in 2015 to a peak of ~1.2 million in 2019, before declining to under 300,000 by 2024 amid competition. It held dominant GLP-1 share pre-2022 but now sits at ~5%.[1][3]
Direct Speed Comparison
Tirzepatide reached liraglutide's 2019 peak sales volume in under two years, versus liraglutide's nine years. Prescription volume growth rate for tirzepatide averaged 150-200% quarterly in 2023-2024, compared to liraglutide's 20-40% in its peak buildup phase (2015-2019). Tirzepatide's superior weight loss efficacy (15-22% body weight reduction vs. liraglutide's 5-8%) and weekly dosing drove faster adoption.[2][4]
Factors Accelerating Tirzepatide's Uptake
Shortage resolutions in 2024 boosted supply, enabling 50%+ quarterly volume jumps. Broader obesity labeling and marketing expanded reach beyond diabetes, unlike liraglutide's slower dual-indication rollout. Patent protection lasts until 2036-2039, shielding growth from generics that eroded liraglutide post-2023.[5]
How Novo Nordisk Responds with Competitors
Novo's semaglutide (Ozempic/Wegovy) now leads overall GLP-1 volume at 45% share, growing 80% YoY to $25 billion in 2024, but tirzepatide is closing the gap faster in obesity. Liraglutide volumes continue shrinking 20-30% annually as patients switch to newer agents.[1][3]
Patient and Payer Trends
U.S. payers cover tirzepatide for 70% of obesity patients (up from 40% in 2023), versus liraglutide's prior 60% peak. Real-world adherence favors tirzepatide's tolerability, with 40% fewer discontinuations.[4]
Sources
[1]: IQVIA National Prescription Audit, 2024
[2]: Eli Lilly Q4 2024 Earnings
[3]: Novo Nordisk Annual Report 2024
[4]: NEJM Real-World Study on GLP-1s, 2024
[5]: DrugPatentWatch.com - Tirzepatide Patents